Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers

Vaccine

Volumn 32, Issue 39, 2014, Pages 5041-5048

  Low, Jenny G H ^a   Lee, Lawrence S ^b,c   Ooi, Eng Eong ^d   Ethirajulu, Kantharaj ^e   Yeo, Pauline ^e   Matter, Alex ^e   Connolly, John E ^f   Skibinski, David A G ^f   Saudan, Philippe ^g   Bachmann, Martin ^g,k   Hanson, Brendon J ^h   Lu, Qingshu ⁱ   Maurer Stroh, Sebastian ^j   Lim, Sam ^e   Novotny Diermayr, Veronica ^e  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHANGI GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e D3 (Drug Discovery and Development)   (Singapore)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^g CYTOS BIOTECHNOLOGY AG   (Switzerland)

^h DSO NATIONAL LABORATORIES   (Singapore)

ⁱ SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

^j BIOINFORMATICS INSTITUTE   (Singapore)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Asians; H1N1; HAI; Influenza; Influenza vaccine; Pandemic; Phase I; Virus like particle; VLP

Indexed keywords

INFLUENZA VACCINE; ALUMINUM HYDROXIDE; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ADULT; ALLERGIC RHINITIS; ANTIBODY RESPONSE; ARTICLE; CATARACT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INTENTION TO TREAT ANALYSIS; MALE; MYALGIA; NORMAL HUMAN; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; RISK ASSESSMENT; SEROCONVERSION; VACCINE PRODUCTION; ANTIBODY PRODUCTION; BIOASSAY; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; MIDDLE AGED; MULTICENTER STUDY; SINGAPORE; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SINGAPORE; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84906080801     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.011     Document Type: Article

References (45)

1. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
2. Smith G.J., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
3. Rappuoli R., Dormitzer P.R. Influenza: options to improve pandemic preparation. Science 2012, 336:1531-1533.
4. Lambert L.C., Fauci A.S. Influenza vaccines for the future. New Engl J Med 2010, 363:2036-2044.
5. Gordon D.L., Sajkov D., Woodman R.J., Honda-Okubo Y., Cox M.M., Heinzel S., et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 2012, 30:5407-5416.
6. Treanor J.J., El Sahly H., King J., Graham I., Izikson R., Kohberger R., et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011, 29:7733-7739.
7. Taylor D.N., Treanor J.J., Sheldon E.A., Johnson C., Umlauf S., Song L., et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012, 30:5761-5769.
8. Taylor D.N., Treanor J.J., Strout C., Johnson C., Fitzgerald T., Kavita U., et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011, 29:4897-4902.
9. Petsch B., Schnee M., Vogel A.B., Lange E., Hoffmann B., Voss D., et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012, 30:1210-1216.
10. Wei C.J., Boyington J.C., McTamney P.M., Kong W.P., Pearce M.B., Xu L., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329:1060-1064.
11. Moser C., Muller M., Kaeser M.D., Weydemann U., Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines 2013, 12:779-791.
12. Gilbert S.C. Advances in the development of universal influenza vaccines. Influenza Other Respir Viruses 2013, 7:750-758.
13. Landry N., Ward B.J., Trépanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza. PLoS One 2010, 5:e15559.
14. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
15. Zhao Q., Li S., Yu H., Xia N., Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 2013, 31:654-663.
16. Lopez-Macias C., Ferat-Osorio E., Tenorio-Calvo A., Isibasi A., Talavera J., Arteaga-Ruiz O., et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011, 29:7826-7834.
17. Tissot A.C., Renhofa R., Schmitz N., Cielens I., Meijerink E., Ose V., et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One 2010, 5:e9809.
18. Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63-72.
19. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005, 35:2031-2040.
20. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008, 3:e2547.
21. Krause M., Ukkonen K., Haataja T., Ruottinen M., Glumoff T., Neubauer A., et al. A novel fed-batch based cultivation method provides high cell-density and improves yield of soluble recombinant proteins in shaken cultures. Microb Cell Fact 2010, 9:11.
22. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
23. Schmitz N., Beerli R.R., Bauer M., Jegerlehner A., Dietmeier K., Maudrich M., et al. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 2012, 42:863-869.
24. Jegerlehner A., Zabel F., Langer A., Dietmeier K., Jennings G.T., Saudan P., et al. Bacterially produced recombinant influenza vaccines based on virus-like particles. PLoS One 2013, 8:e78947.
25. Skibinski D.A.G., Hanson B.J., Lin Y., von Messling V., Jegerlehner A., Tee J.B.S., et al. Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. PLoS One 2013, 8:e76571.
26. Sharma S., Whalley A., McLaughli J., Brello F., Bishop B., Banerjee A. Fermentation process technology transfer for production of a recombinant vaccine component. BioPharm Int 2011, 3:0-9.
27. MedDRA® Term Selection V Application to adverse drugs reactions/adverse events & and medical and social history & indications. Version 121 2009, ICH, Geneva.
28. FDA Toxicity scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials, FDA 2007, FDA.
29. FDA Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines 2007, FDA.
30. Czajka H., Unal S., Ulusoy S., Usluer G., Strus A., Sennaroglu E., et al. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. J Prev Med Hyg 2012, 53:136-142.
31. Tambyah P.A., Wilder-Smith A., Pavlova B.G., Barrett P.N., Oh H.M., Hui D.S., et al. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 2012, 30:329-335.
32. Gurwith M., Lock M., Taylor E.M., Ishioka G., Alexander J., Mayall T., et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013, 13:238-250.
33. Seidman J.C., Richard S.A., Viboud C., Miller M.A. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses 2012, 6:52-62.
34. Arnou R., Eavis P., Pardo J.R., Ambrozaitis A., Kazek M.P., Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: randomized, controlled, phase III trial. Hum Vaccines 2010, 6:346-354.
35. Precioso A.R., Miraglia J.L., Campos L.M., Goulart A.C., Timenetsky Mdo C., Cardoso M.R., et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. Vaccine 2011, 29:8974-8981.
36. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
37. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367:1657-1664.
38. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. New Engl J Med 2008, 358:2573-2584.
39. Ikeno D., Kimachi K., Kudo Y., Goto S., Itamura S., Odagiri T., et al. A prime-boost vaccination of mice with heterologous H5N1 strains. Vaccine 2009, 27:3121-3125.
40. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6:685-698.
41. Brady R.C., Treanor J.J., Atmar R.L., Keitel W.A., Edelman R., Chen W.H., et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27:5091-5095.
42. Dong A., Jones L.S., Kerwin B.A., Krishnan S., Carpenter J.F. Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations. Anal Biochem 2006, 351:282-289.
43. Jones L.S., Peek L.J., Power J., Markham A., Yazzie B., Middaugh C.R. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005, 280:13406-13414.
44. Barr I.G., Cui L., Komadina N., Lee R.T., Lin R.T., Deng Y., et al. A new pandemic influenza A(H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore. Eurosurveillance 2010, 15. (Bulletin Europeen sur les maladies transmissibles[[nl]]European communicable disease bulletin), pii19692.
45. Strengell M., Ikonen N., Ziegler T., Julkunen I. Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties. PLoS One 2011, 6:e25848.